OK, so with my conspiracy theorist, tin-foil hat on, here goes:
I think something is coming out of left field from Denner and Amarin. I don't think all is as it seems. And I think they are going to use retail investor's impatience against them.
1. It seems that WS does not understand the inherent value in Vascepa. Most WS analysts are idiots. They are robots that are trained to analyze balance sheets and make forward-looking assumptions about revenue growth, DCF, etc. Any monkey with Excel can do what most of them do. So you can't put much "stock" in the current SP or analyst reports. All they are thinking about is the profitability of Amarin. They are treating it like a company that is going operate indefinitely. But it's not. WE all know it. Denner knows it. Amarin knows it. Who really cares if "Amarin" is profitable? How many small bio-techs that were sold for billions were profitable? It doesn't matter.
2. You want to know what matters? Enough cash to continue operating. Does anyone think that Q1 REALLY took Amarin by surprise? Did they SEEM surprised? Does anyone think Q2 is going to be any BETTER? With scripts going DOWN? And costs going UP?
3. Does it seem curious why Denner has apparently said nothing. But he's obviously made a lot of board moves. And why KM does not really seem that concerned about script slippage, negative cashflow, etc.? Even though, as said above, it's only going to get WORSE? We won't see any EU scripts in 2022 (nothing meaningful anyway). And we won't see anything from China either. So cash is going to continue to bleed.
4. Why does the company seem somewhat indifferent to investors' concerns?
5. The new board choices are interesting, and telling. PWO was hand-picked by Denner (he was on the board of Gilead for 10+ yrs, one of Sarissa's largest holdings). And take a look at a snippet from Prettybrook's website:
Prettybrook is often the preferred partner of venture capital and private equity firms, management teams and sellers. Our ideal transaction is one in which we invest side-by-side with venture or private equity backers.
Transaction Types (read this section a few times)
Control-oriented leveraged buyouts of privately-held businesses, corporate divisions, and public companies
Restructuring/recapitalizations of privately-held businesses
Staged transitions of corporate-owned entities
Partnerships with other strategic and financial buyers
Going-private transactions
5. Where do you think the cash is going to come from? Longs are about to get FUBAR by Denner, Prettybrook, and Amarin. I think Amarin is sitting on a goldmine and Denner & Prettybrook know it. And they are going to take themselves to the Promised Land.
Is the light starting to come on? All is not as it seems.
Market Data 
Markets 
AI
